Wegovy
The brand name for high-dose semaglutide (2.4mg weekly) approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
What does Wegovy mean in peptide research?
The brand name for high-dose semaglutide (2.4mg weekly) approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. This term is part of the broader field of peptide research, which encompasses both FDA-approved therapeutic peptides and research-grade compounds used in scientific investigation.
Why this term matters
Understanding Wegovy is foundational for anyone reviewing peptide research literature, comparing different research compounds, or following regulatory developments in this field. The term appears across pharmacology textbooks, FDA documentation, and clinical trial reports.
Where to learn more
For deeper context, see our peptide research articles: